KIDS vs LEGN: fair value comparison
OrthoPediatrics Corp. and Legend Biotech Corporation · Updated 2026-10-19
KIDS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. LEGN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, KIDS currently ranks higher by quality score.
| KIDS | LEGN | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $21.95 | $18.48 |
| 12-month range | $14.64–$26.50 | $16.65–$36.28 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #84 of 301 Healthcare | #85 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: KIDS fair value analysis · LEGN fair value analysis